6-氯-4-氨基喹唑啉 | 19808-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 6-氯-4-氨基喹唑啉
• 中文别名: 6-氯喹唑啉-4-胺
• 英文名称: 4-amino-6-chloroquinazoline
• 英文别名: 6-chloroquinazolin-4-amine；6-chloro-quinazolin-4-ylamine；4-amino-6-chloro-quinazoline；4-Amino-6-chlorchinazolin
• CAS: 19808-35-6
• 化学式: C₈H₆ClN₃
• mdl: MFCD02676502
• 分子量: 179.609
• InChiKey: KMYOLSIBCDCWQQ-UHFFFAOYSA-N

物化性质

• 熔点：
  >310 °C
• 沸点：
  363.2±27.0 °C(Predicted)
• 密度：
  1.445±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloroquinazolin-4-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloroquinazolin-4-amine
CAS number: 19808-35-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6ClN3
Molecular weight: 179.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氯-4-氨基喹唑啉 在 盐酸羟胺 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 10.0h， 生成 N-[4-chloro-2-([1,2,4]oxadiazol-5-yl)phenyl]formamide oxime
  参考文献：
  名称：

  多环N-杂环化合物，第67部分：6,7-取代的N-（喹唑啉-4-基）am衍生物与盐酸羟胺的反应：戊糖苷体外抑制剂的形成

  摘要：

  的反应ñ - （喹唑啉-4-基）脒和与盐酸羟胺它们的酰胺肟，得到由嘧啶成分的初始环切割被形成的环化产物，随后的-1,2,4-恶二唑，得到环闭合形成N- [2-（[[1,2,4]恶二唑-5-基）苯基]甲酰胺肟。评价所有分离的产物对戊糖苷形成的体外抑制活性，戊糖苷是代表性的高级糖基化终产物之一。一些产品显示出对戊糖苷形成的显着抑制活性。J.杂环化​​学。（2011）。

  DOI：

  10.1002/jhet.695
• 作为产物：
  描述：

  5-氯靛红酸酐 以72%的产率得到
  参考文献：
  名称：

  FOSTER C. H.; ELAM E. U., J. ORG. CHEM. , 1976, 41, NO 15, 2646-2647

  摘要：

  DOI：

文献信息

• Cu/<i>N</i>,<i>N</i>′-Dibenzyloxalamide-Catalyzed <i>N</i>-Arylation of Heteroanilines
  作者：Zhixiang Chen、Dawei Ma

  DOI：10.1021/acs.orglett.9b02509

  日期：2019.9.6

  N,N'-Dibenzyloxalamide (DBO) was identified as a powerful ligand for promoting Cu-catalyzed coupling of heteroanilines with (hetero)aryl halides. For (hetero)aryl chlorides, the coupling reaction occurred at 130 °C with 5 mol % CuBr and 10 mol % DBO. For (hetero)aryl bromides/iodides, coupling reaction took place at 80-100 °C with 1 mol % CuI and 2 mol % DBO. A variety of heteroanilines worked well

  N，N'-二苄基草酰胺（DBO）被确定为一种强大的配体，用于促进Cu催化杂苯胺与（杂）芳基卤化物的偶联。对于（杂）芳基氯，偶联反应在130℃下与5mol％的CuBr和10mol％的DBO发生。对于（杂）芳基溴化物/碘化物，偶合反应在80-100°C下与1 mol％的CuI和2 mol％的DBO进行。各种杂苯胺效果很好，以高到极高的收率提供了芳基化产物。
• [EN] SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS<br/>[FR] DIHYDROIMIDAZOPYRIDINEDIONES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE MKNK1 ET DE MKNK2
  申请人：BAYER PHARMA AG

  公开号：WO2018134148A1

  公开（公告）日：2018-07-26

  The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (A) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（A）所描述和定义的取代二氢咪唑吡啶二酮化合物，以及制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和复合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物，特别是治疗过度增殖、血管生成障碍、炎症性疾病或与炎症性疼痛相关的疾病的药物组合物，作为单一药剂或与其他活性成分结合使用。
• Sodium salt of
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04429126A1

  公开（公告）日：1984-01-31

  Quinazoline derivatives of the formulae: ##STR1## wherein A.sup.1 is ##STR2## A.sup.2 is ##STR3## R.sup.1 is hydrogen, carboxy or esterified carboxy, R.sub.a.sup.1 and R.sub.b.sup.1 are esterified carboxy, R.sup.2 and R.sup.3 are hydrogen, alkyl, halogen, nitro, amino, alkoxy, aryloxy, alkylthio, alkylpiperazinyl, acylamino or dialkylamino which may be substituted with hydroxy, R.sup.4 is hydrogen, alkyl, hydroxy, alkoxy, alkenyloxy, dialkylamino or 2,2-dialkoxycarbonylvinylamino R.sub.a.sup.4 is hydrogen, alkyl, hydroxy, alkoxy, alkenyloxy or dialkylamino, R.sup.5 is alkyl or alkenyl, and R.sup.6 is carboxy or esterified carboxy.

  Quinazoline衍生物的化学式如下：##STR1## 其中A.sup.1是##STR2## A.sup.2是##STR3## R.sup.1是氢、羧基或酯化羧基，R.sub.a.sup.1和R.sub.b.sup.1是酯化羧基，R.sup.2和R.sup.3是氢、烷基、卤素、硝基、氨基、烷氧基、芳氧基、烷硫基、烷基哌嗪基、酰胺基或二烷基胺基，可能被羟基取代，R.sup.4是氢、烷基、羟基、烷氧基、烯烯氧基、二烷基胺基或2,2-二烷氧羰基乙烯氨基，R.sub.a.sup.4是氢、烷基、羟基、烷氧基、烯烯氧基或二烷基胺基，R.sup.5是烷基或烯烃基，R.sup.6是羧基或酯化羧基。
• Tricyclic quinazoline derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04377580A1

  公开（公告）日：1983-03-22

  Quinazoline derivatives of the formulae: ##STR1## wherein A.sup.1 is ##STR2## A.sup.2 is ##STR3## R.sup.1 is hydrogen, carboxy or esterified carboxy, R.sub.a.sup.1 and R.sub.b.sup.1 are esterified carboxy, R.sup.2 and R.sup.3 are hydrogen, alkyl, halogen, nitro, amino, alkoxy, aryloxy, alkylthio, alkylpiperazinyl, acylamino or dialkylamino which may be substituted with hydroxy, R.sup.4 is hydrogen, alkyl, hydroxy, alkoxy, alkenyloxy, dialkylamino or 2,2-dialkoxycarbonylvinylamino R.sub.a.sup.4 is hydrogen, alkyl, hydroxy, alkoxy, alkenyloxy or dialkylamino, R.sup.5 is alkyl or alkenyl, and R.sup.6 is carboxy or esterified carboxy.

  配方为：##STR1## 的喹唑啉衍生物，其中A.sup.1是##STR2##，A.sup.2是##STR3##，R.sup.1是氢、羧基或酯化羧基，R.sub.a.sup.1和R.sub.b.sup.1是酯化羧基，R.sup.2和R.sup.3是氢、烷基、卤素、硝基、氨基、烷氧基、芳氧基、烷硫基、烷基哌嗪基、酰基氨基或二烷基氨基，可以被羟基取代，R.sup.4是氢、烷基、羟基、烷氧基、烯基氧基、二烷氨基或2,2-二烷氧羰基乙烯基氨基，R.sub.a.sup.4是氢、烷基、羟基、烷氧基、烯基氧基或二烷基氨基，R.sup.5是烷基或烯基，R.sup.6是羧基或酯化羧基。
• [EN] HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS<br/>[FR] DERIVES HETEROCYCLIQUES ET LEUR UTILISATION EN TANT QU'AGENTS ANTITHROMBOTIQUES
  申请人：AKZO NOBEL N.V.

  公开号：WO1998047876A1

  公开（公告）日：1998-10-29

  (EN) The present invention relates to antithrombotic compounds comprising the group Q, Q having formula (I), wherein the substructure (i) is a structure selected from (a, b and c), wherein X is O or S; X' being independently CH or N; and m is 0, 1, 2 or 3; wherein the group Q is bound through an oxygen atom or an optionally substituted nitrogen or carbon atom, or a pharmaceutically acceptable salt thereof or a prodrug thereof. The compounds of the invention are therapeutically active and in particular are antithrombotic agents.(FR) La présente invention concerne des composé antithrombotiques comprenant le groupe Q correspondant à la formule (I) dans laquelle la sous-structure (i) est une structure choisie parmi (a), (b) ou (c) où X représente O ou S, X' représente indépendamment CH ou N, et m vaut 0, 1, 2 ou 3, le groupe Q étant fixé au moyen d'un atome d'oxygène ou d'un atome de carbone ou d'azote éventuellement substitué. L'invention concerne également un sel ou un promédicament de ces composés, acceptable sur le plan pharmacologique. Les compositions de l'invention sont actives sur le plan thérapeutique et constituent notamment des agents antithrombotiques.

  该发明涉及抗血栓化合物，包括具有公式（I）的Q基团，其中亚结构（i）是从（a）、（b）和（c）中选择的结构，其中X为O或S；X'独立地为CH或N；m为0、1、2或3；其中Q基团通过氧原子或可选择的取代氮或碳原子结合，或其药学可接受的盐或前药。该发明的化合物具有治疗活性，特别是抗血栓剂。